Search

Your search keyword '"Rozentale B."' showing total 150 results

Search Constraints

Start Over You searched for: Author "Rozentale B." Remove constraint Author: "Rozentale B."
150 results on '"Rozentale B."'

Search Results

1. Trends in mortality in people with HIV from 1999 to 2020: a multi-cohort collaboration

2. Management of MDR-TB in HIV co-infected patients in Eastern Europe: Results from the TB:HIV study

3. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy

5. Healthcare delivery for HIV-positive people with tuberculosis in Europe

6. Delayed diagnosis of tuberculosis in persons living with HIV in Eastern Europe: associated factors and effect on mortality—a multicentre prospective cohort study

7. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy: A multinational prospective cohort study

8. Incidence of cancer and overall risk of mortality in individuals treated with raltegravir‐based and non‐raltegravir‐based combination antiretroviral therapy regimens

9. The extent of B‐cell activation and dysfunction preceding lymphoma development in HIV‐positive people†

10. Delayed diagnosis of tuberculosis in persons living with HIV in Eastern Europe: associated factors and effect on mortality-a multicentre prospective cohort study

11. Gender differences in the use of cardiovascular interventions in HIV?positive persons; the D:A:D Study

12. The present and future disease burden of hepatitis C virus infections with todayʼs treatment paradigm – volume 3

13. Historical epidemiology of hepatitis C virus (HCV) in select countries – volume 3

14. Strategies to manage hepatitis C virus infection disease burden – volume 3

15. Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens

16. Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA

19. Healthcare delivery for HIV-positive people with tuberculosis in Europe

20. Delayed diagnosis of tuberculosis in persons living with HIV in Eastern Europe:associated factors and effect on mortality—a multicentre prospective cohort study

21. Healthcare delivery for HIV-positive people with tuberculosis in Europe

24. Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy

25. Long‐term effectiveness of recommended boosted protease inhibitor‐based antiretroviral therapy in Europe

30. Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe

31. Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA

32. Liver-related death among HIV/hepatitis C virus-co-infected individuals

33. Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe

34. Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort

35. Major differences in organization and availability of health care and medicines for HIV/TB coinfected patients across Europe

36. Major differences in organization and availability of health care and medicines for HIV/TB coinfected patients across Europe

37. Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens

38. Management of MDR-TB in HIV co-infected patients in Eastern Europe: Results from the TB:HIV study

39. Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens

41. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study

42. Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression : A prospective cohort study

43. Tuberculosis among HIV-positive patients across Europe: changes over time and risk factors

44. Management of MDR-TB in HIV co-infected patients in Eastern Europe: Results from the TB:HIV study

45. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study

46. Infection-related and -unrelated malignancies, HIV and the aging population

47. Tuberculosis-related mortality in people living with HIV in Europe and Latin America: An international cohort study

48. Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study

49. Hyaluronic acid levels predict risk of hepatic encephalopathy and liver-related death in HIV/viral hepatitis coinfected patients

50. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study

Catalog

Books, media, physical & digital resources